News

GRI Bio's Upcoming Presentation at Annual Investment Conference

GRI Bio's Upcoming Presentation at Annual Investment Conference

GRI Bio's Upcoming Presentation at the Annual Investment Conference

GRI Bio, Inc. (NASDAQ: GRI), an innovative biotechnology firm specializing in Natural Killer T (NKT) cell modulators, is gearing up for a significant presentation at the H.C. Wainwright 26th Annual Global Investment Conference. This event is set to occur from September 9 to September 11, 2024, in New York City. Dr. Marc Hertz, the Chief Executive Officer of GRI Bio, will lead the presentation.

What to Expect from the Presentation

At this pivotal event, GRI Bio plans to provide valuable insights into its groundbreaking therapies aimed at treating inflammatory, fibrotic, and autoimmune diseases. Dr. Hertz will discuss the company's recent advancements and engage with attendees about future opportunities. Additionally, the management team will participate in one-on-one meetings with qualified investors who are registered for the conference.

Investors Can View the Webcast

For those unable to attend in person, a video webcast of the presentation will be available for on-demand viewing. The webcast will be accessible starting on September 9, 2024, at 7:00 AM ET, and can be found on the Events page in the Investors section of GRI Bio’s official website. Furthermore, GRI plans to archive the webcast replay for 90 days after the event, allowing all interested investors and stakeholders to catch up on the presentation at their convenience.

About GRI Bio, Inc.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company that is transforming the treatment landscape for inflammatory, fibrotic, and autoimmune diseases. By concentrating on modulating NKT cell function, which plays a crucial role in regulating immune responses, GRI Bio aims to halt disease progression and restore immune balance. Their lead candidate, GRI-0621, effectively inhibits iNKT cell activity and is being developed as a novel oral therapy specifically for idiopathic pulmonary fibrosis, a serious condition with significant unmet medical needs. The company is also advancing a promising pipeline of novel type 2 NKT agonists designed to treat systemic lupus erythematosus, underscoring its commitment to tackling critical health challenges.

Investor Relations Contact

For additional inquiries, investors can reach out to the JTC Team, led by Jenene Thomas. She can be contacted at (833) 475-8247, and emails can be sent to GRI@jtcir.com.

Frequently Asked Questions

1. When will GRI Bio present at the conference?

The presentation is scheduled for September 9-11, 2024, at the H.C. Wainwright Annual Global Investment Conference.

2. Who will be presenting for GRI Bio?

Dr. Marc Hertz, the Chief Executive Officer, will represent GRI Bio during the conference.

3. Is there a way to watch the presentation remotely?

Yes, there will be a video webcast available for on-demand viewing starting September 9, 2024, at 7:00 AM ET.

4. What is GRI Bio's primary focus?

GRI Bio focuses on developing therapies that modulate NKT cells to treat inflammatory, fibrotic, and autoimmune diseases.

5. How can investors contact GRI Bio for more information?

Investors can contact Jenene Thomas at (833) 475-8247 or via email at GRI@jtcir.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

XKL Delivers MediaLight for High-Speed Optical Transport

Updated Category News Views 2

Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...

Continue Reading
Moore Law Investigates Aardvark Therapeutics' Risks

Updated Category News Views 2

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Continue Reading
Insurance Bad Faith: Navigating California's Rigorous Laws

Updated Category News Views 4

Understanding What Constitutes Bad Faith Insurance What does it really mean when an insurer acts in "bad faith"? Well, the legal standard doesn't leave much wiggle room in California. These aren't just bad outcomes; we're talking about conduct that defies what's reasonable under state law. Demián I. Oksenendler, a seasoned bad faith attorney, shed some light on this in a...

Continue Reading
BusyBee AI Revolutionizes Classroom Feedback Efficiency

Updated Category News Views 3

Grading Overhaul: BusyBee's Role in Education Here's a twist for the history books: Agilix Labs' BusyBee, a slick AI assistant built right into the Buzz platform on Amazon Bedrock, is kicking traditional grading methods to the curb. This little helper is grading close to a million K-12 student submissions every month, meticulously approved by real teachers. Quite the...

Continue Reading
Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Updated Category News Views 4

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Continue Reading
AI Trust in Finance: Survey Reveals Market Impact

Updated Category News Views 3

Trust in AI for Financial Guidance: Where Are We Headed? The market winds shift with every sunrise, and today’s buzzword? Artificial Intelligence. You’d almost think AI’s trying to steal my job along with every other trader’s mojo. But here's the twist—A survey from Possible Finance shows about 15% of folks would actually lean on AI for their financial advice....

Continue Reading
Albertsons Welcomes Once Upon a Coconut Nationwide

Updated Category News Views 4

Coconut Water Takes Over Grocery Aisles You know, for all the cautious optimism I wield, this here is a move that shows real muscle in the world of coconut water—I mean, slamming into Albertsons' grocery empire is no small potatoes! Once Upon a Coconut has landed its premium hydration cans across all the banners under this giant retailer. From that good ol' familiar...

Continue Reading
Liberty Hill: 50 Years of Grassroots Revolution

Updated Category News Views 4

Half a Century of Community Empowerment You don't see organizations sticking to their guns for fifty years without having something real to offer. Liberty Hill Foundation is celebrating this colossal milestone in style by throwing their weight behind 17 grassroots groups under the 2026 Fund for Change. They're not just tossing money around but are genuinely becoming the...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 4

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading
Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Updated Category News Views 6

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Continue Reading

Top 5 Most Recently Viewed Articles

Temporary Suspension of Trading Affecting Several Funds

Updated Category News Views 188

Temporary Suspension of Trading for Specific Funds Sparinvest has announced a temporary suspension of trading for several of its funds. This action is taken in light of challenges experienced in reporting the net asset values to Nasdaq Copenhagen due to unforeseen technical issues. As a responsible entity, Sparinvest is committed to maintaining transparency and ensuring...

Continue Reading
Compugen Announces Upcoming Participation in Healthcare Event

Updated Category News Views 65

Compugen to Join Prominent Healthcare Conference Compugen Ltd. (Nasdaq: CGEN), renowned for its innovative strategies in cancer immunotherapy and computational target discovery, is set to engage in a fireside chat during the forthcoming Stifel 2024 Healthcare Conference. This engaging discussion will take place on a day when industry leaders congregate to share insights...

Continue Reading
Matz Injury Law Unveils Reduced Fees Resulting in Major Savings

Updated Category News Views 125

Matz Injury Law's Innovative Fee Structure In a significant move that enhances client financial stability, Matz Injury Law has announced over $10 million in savings for its clients through a uniquely structured contingency fee model. The Southfield-based personal injury law firm, founded by Steve Matz in 1978, offers its clients a low contingency fee of 22%, a marked...

Continue Reading
IBM Links Arms with Abertis: Major Technology Deal

Updated Category News Views 6

Revolutionizing Mobility with a Tech Overhaul In a world where digital transformation isn't just a buzzword but a business imperative, IBM (NYSE: IBM) has strapped in for a new ride, joining forces with Abertis, an infrastructure heavyweight. These folks aren't just tapping on a few keyboards here—they're looking to give the entire mobility sector a facelift with a...

Continue Reading
Mercer Enhances Global Pension Services with Cardano Acquisition

Updated Category News Views 30

Mercer Completes Strategic Acquisition of Cardano In a significant move for the financial services sector, Mercer, a prominent business of Marsh McLennan (NYSE: MMC), successfully completed its acquisition of Cardano, a professional services firm known for its expertise in pension services and investment solutions. This acquisition marks a strategic enhancement for...

Continue Reading